Abstract
The purpose of the study was to determine the differences in the financial performance of companies producing COVID-19 vaccines, before and after the pandemic. The method using the company's financial statement data for 2017-2021, then analyzed with the parameters current ratio, debt to equity ratio, return on assets, return on equity, and net profit margin. The study found that the company's strategic decision to develop a COVID-19 vaccine did not guarantee an increase in the company's financial performance. Moderna has focused on developing treatment with mRNA technology, so there has been a drastic change from the worst financial performance company to the best in 2021. Meanwhile, AstraZeneca has been experiencing financial difficulties since before pandemic failed to restore its financial performance profile in 2021. Pfizer, Johnson & Johnson, and Sinopharm shows a stable financial performance profile both before and after the COVID-19 pandemic. Keywords: financial performance, COVID-19 vaccine, current ratio, debt to equity, return on asset, return on equity, net profit margin DOI: 10.7176/JHMN/102-03 Publication date: October 31 st 2022
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
